LDX

LUMOS FPO [LDX]
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Healthcare · ASX Small Cap
$0.0800 -4.8%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when LDX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track LDX — Free

Active Signals

Bullish Signals

  • RSI is looking oversold — historically a spot where stocks tend to bounce
  • MACD momentum is losing steam
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Drifting lower — down 7.0% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.75, underperforming its peers
  • Adequate cash runway (5 quarters)
  • Moderate P/S ratio (6.2x)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (8% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (19%)
  • Sentiment is mixed — no strong consensus either way
  • Beneish M-Score -1.98 (grey zone -2.22 to -1.78): possible earnings manipulation
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 9d (+5pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Broke below 20-day support — that's a level the market was defending, and it just gave way
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-76%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 26% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.86%/day)
Ask Scout AI about LDX
"What's driving LDX today?" "How does LDX compare to peers?" "Key risks for LDX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Q4 FY26 Results Release Date and Webinar Invitation
NONE Investor Information Sessions
NONE Notification of cessation of securities - LDX

Recent ASX Announcements

2026-07-20 Q4 FY26 Results Release Date and Webinar Invitation
2026-07-20 Investor Information Sessions
2026-07-14 Notification of cessation of securities - LDX
2026-07-02 Closure of A$5M Loan Facility with Major Shareholders
2026-06-28 Lumos Receives Research & Development Tax Rebate PRICE SENSITIVE

Key Metrics

$75.6M
Market Cap
2.5M
Avg Volume
1.1x
Vol Ratio
$0.06 — $0.33
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-123.3%
ROE
-75.8%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 51%
LLeader vs LaggardlaggardRS: -14
IInstitutional SponsorshippassInst: 19%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:LDX vs ECSLDX vs VHLLDX vs NTI
Scout Pro — Deeper Analysis for LDX
Try Pro free for 30 days
Share this analysis

Track LDX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required